Navata
← All Library

Validation & Evidence

When Can Automated Testing Be Used as GxP Validation Evidence?

AI-assisted research and drafting · Practitioner reviewed by Rohith Karanam Sreedhar · 16 September 2026

ⓘ Library content is researched and drafted with AI assistance and reviewed by a Navata practitioner before publication. For original analysis and long-form practitioner perspectives, visit Navata Insights →

Automating a weak test only produces weak evidence faster. The assurance question is not whether a robot clicked the buttons. It is whether the automated execution reliably challenged the right claim under known conditions and left a record that can be reconstructed.

Choose claims that automation can observe

Automation is strong where expected behaviour is deterministic and observable. Examples include repeatable regression checks, calculations, API responses, data transformations, permission outcomes and high-volume combinations with stable acceptance criteria.

It is weaker where the important evidence depends on human judgement, usability, procedural understanding or interpretation of an unexpected state. Those claims may still use automated preparation or data capture, but the final assurance conclusion may need competent human observation.

Control the test logic as part of the evidence chain

The automated script, model or workflow that performs the test is not neutral simply because it is a test tool. Establish who owns it, how changes are controlled, what version executed, what dependencies it uses and how it was shown to perform the intended test correctly.

A regulated team does not necessarily need to validate every test utility as if it were the production system. The level of assurance should follow the risk that an incorrect tool result could create false confidence. The key is to know where the test result depends on the tool and what independent checks are appropriate.

Bind the run to the system state

Retain enough context to show what was actually tested. At minimum, the evidence should make clear the system or build version, relevant configuration, test environment, data or input set, automated script version, execution identity or tool identity, date and result.

If a test is rerun after a failure, preserve the failed result and link it to the defect or deviation and subsequent run. A dashboard that only shows the latest green status is not an adequate history where prior failures affected the validation decision.

Keep acceptance criteria outside the execution result

The automation should not silently decide what counts as acceptable by using undocumented thresholds. Acceptance criteria should be defined and reviewable before the run, or the rationale for dynamic criteria should be controlled separately.

EMA's clinical-trial computerised-systems guideline explicitly states that test cases may be held in test-management systems that allow automatic execution, including regression testing. It also expects the identity of an automatic testing tool to be documented where relevant. This is useful evidence that automated execution is compatible with a controlled validation approach within that guideline's stated scope.

Treat logs as evidence, not as volume

More log output is not automatically better. Retain evidence that supports the assurance claim: inputs, execution status, failed assertions, timestamps, relevant outputs and links to the controlled test definition. Excess diagnostic noise can make review harder without improving confidence.

Where screenshots are not meaningful for an API or background process, machine-readable logs or reconciled output may be stronger evidence. The evidence form should match the behaviour being tested.

Use human review at the right point

Human review should focus on whether the test design is adequate, failures were correctly interpreted and the result supports release. It should not require a person to manually reproduce every automated step merely to make the record look traditional.

FDA's February 2026 Computer Software Assurance guidance supports risk-based assurance methods for software used in medical-device production or quality management systems. Its scope should not be silently extended to all pharmaceutical GxP systems, but it reinforces the principle that assurance effort and evidence should be proportionate to risk.

Important boundaries

The EMA source is specific to computerised systems used in clinical trials, and FDA CSA has its own device-production/QMS scope. EU GMP Annex 11 remains the general GMP computerised-system baseline cited here. None of these sources makes automated testing acceptable by label alone.

Sources